Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1-receptor antagonist

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 3, 1999, Pages 367-374

  Lee, Sung Ho ^a   Jung, Yi Sook ^a,b   Lee, Byung Ho ^a   Yun, Sun Il ^a   Yoo, Sung Eun ^a   Shin, Hwa Sup ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Ajou University School of Medicine   (South Korea)

Author keywords

Angiotensin; AT1 receptor antagonist; KR 31080; SK 1080

Indexed keywords

1 (4 AMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDROIMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 BUTYL 5 METHYL 6 (OXOPYRIDIN 2 YL) 3 [[2' (TETRAZOL 5 YL)BIPHENYL 4 YL]METHYL]IMIDAZO[4,5]PYRIDINE; 2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; LOSARTAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SCATCHARD PLOT;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA, THORACIC; BINDING, COMPETITIVE; BLOOD PRESSURE; DECEREBRATE STATE; DIASTOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; IMIDAZOLES; LOSARTAN; MALE; MUSCLE CONTRACTION; PYRIDINES; RABBITS; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; SENSITIVITY AND SPECIFICITY; TETRAZOLES;

EID: 0033041021     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199903000-00004     Document Type: Article

References (25)

1. Vallotton MB. The renin-angiotensin system. Trends Pharmacol Sci 1987;8:69-74.
2. Corvol P, Chauveau D, Jeunemaitre X, Menard J. Human renin inhibitor peptides. Hypertension 1990;16:1-11.
3. Cody RJ. Conceptual and therapeutic approaches to inhibition of the renin-angiotensin system in chronic heart failure. J Cardiovasc Pharmacol 1986;8(suppl 1):S58-65.
4. Williams GH. Converting enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988;319:1517-25.
5. Gravas H, Gravas I. Angiotensin converting enzyme inhibitors: properties and side effects. Hypertension 1988;11(suppl II):II37-41.
6. Roberts JR, Wuertz RC. Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema. Ann Emerg Med 1991;20:555-8.
7. Coulter DM, Edwards IR. Cough associated with captopril and enalapril. Br Med J 1987;294:1521-3.
8. Okunishi H, Miyazaki M, Okamura T, Toda N. Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem Biophys Res Commun 1987;149:1186-92.
9. Okamura T, Okunishi H, Ayajiki K, Toda. N. Conversion of angiotensin I to angiotensin II in dog isolated renal artery: role of two different angiotensin II-generating enzymes. J Cardiovasc Pharmacol 1990;15:353-9.
10. Wienen W, Mauz AB, Van Meel JC, Entzeroth M. Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies. Mol Pharmacol 1992;41:1081-8.
11. Timmermans PB, Smith RD. Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur Heart J 1994;15(suppl D):79-87.
12. Wong PC, Price WA, Chiu AT, et al. In vivo pharmacology of DuP 753. Am J Hypertens 1991;4:288S-98S.
13. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists: IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990;252:726-32.
14. Wong PC, Hart SD, Duncia JV, Timmermans PB. Nonpeptide angiotensin II receptor antagonists: studies with DuP 753 and EXP3174 in dogs. Eur J Pharmacol 1991;202:323-30.
15. Mallion J-M, Goldberg AI. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension. Blood Press 1996;5:82-6.
16. Dahlof B, Keller SE, Makris L, Goldberg AI, Sweet CS, Lim NY. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995;8:578-83.
17. Dickstein K, Gottlieb S, Fleck E, et al. Hemodynamic and neuro-humoral effects of the angiotensin II antagonist losartan in patients with heart failure. J Hypertens 1994;12:S31-5.
18. 50) of an enzyme reaction. Biochem Pharmacol 1973;22:3099-108.
19. Schild HO. pA, a new scale for the measurement of drug antagonism. Br J Pharmacol 1947;2:189-206.
20. Gillespie JS, Muir TC. A method of stimulating the complete sympathetic outflow from the spinal cord to blood vessels in the pithed rat. Br J Pharmacol 1967;30:78-87.
21. Wienen W, Hauel N, Van Meel JC, Narr B, Ries U, Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993;110:245-52.
22. 1 receptor antagonist. J Pharmacol Exp Ther 1995;272:750-7.
23. Cazes M, Provost D, Versigny A, Cloarec A. In vivo pharmacological characterization of UP 269-6: a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995;284:157-70.
24. 1 antagonism. J Pharmacol Exp Ther 1995;273:753-61.
25. Bond RA, Ornstein AG, Clarke DE. Unsurmountable antagonism to 5-hydroxytryptamine in rat kidney results from pseudoirreversible inhibition rather than multiple receptors or allosteric receptor modulation. J Pharmacol Exp Ther 1989;249:401-10.